Comparative Pharmacology
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus PERTOFRANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMIPRAMINE PAMOATE versus PERTOFRANE.
IMIPRAMINE PAMOATE vs PERTOFRANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imipramine is a tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at presynaptic neuronal membranes, increasing their concentrations in the synaptic cleft. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Tricyclic antidepressant that inhibits the reuptake of norepinephrine and serotonin at the presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
150-300 mg orally once daily at bedtime for depression; 75-150 mg/day for panic disorder.
150-300 mg oral in divided doses per day; 75-150 mg IM in divided doses per day
None Documented
None Documented
11-25 hours (mean 19 h); extended in elderly (up to 30 h) and hepatic impairment; clinical context: steady-state reached in 7-14 days
Terminal elimination half-life is 14–21 hours. Steady-state is reached within 5–7 days. The half-life is prolonged in elderly and patients with hepatic impairment.
Primarily renal (70% as metabolites, <5% unchanged); 20-30% fecal via biliary excretion
Primarily renal (70%), with 30% as unchanged drug; remainder as glucuronide and sulfate conjugates. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant